A multicenter phase I trial of interferon-β and temozolomide combination therapy for high-grade gliomas (INTEGRA Study)

Japanese Journal of Clinical Oncology

Volumn 38, Issue 10, 2008, Pages 715-718

  Wakabayashi, Toshihiko ^a   Kayama, Takamasa ^b   Nishikawa, Ryo ^c   Takahashi, Hiroshi ^d   Yoshimine, Toshiki ^e   Hashimoto, Nobuo ^f   Aoki, Tomokazu ^g   Kurisu, Kaoru ^h   Natsume, Atsushi ^a   Ogura, Masatoshi ^a   Yoshida, Jun ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d NIPPON MEDICAL SCHOOL   (Japan)

^e OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^f KYOTO UNIVERSITY   (Japan)

^g Kitano Hospital   (Japan)

^h HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemo phase I II III; Clinical trials; CNS

Indexed keywords

BETA INTERFERON; TEMOZOLOMIDE;

ARTICLE; BLOOD TOXICITY; CANCER INCIDENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FOLLOW UP; GLIOBLASTOMA; HUMAN; JAPANESE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; POPULATION RESEARCH; SOLID TUMOR; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 54949139977     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn095     Document Type: Article

References (14)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
2. Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Nat Acad Sci USA 1998;95:5724-9.
3. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, et al. Genetic pathways to glioblastoma: A population-based study. Cancer Res 2004;64:6892-9.
4. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479-89.
5. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323-9.
6. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
7. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, et al. Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003;8:237-49.
8. Wakabayashi T, Hatano N, Kajita Y, Yoshida T, Mizuno M, Taniguchi K, et al. Initial and maintenance combination treatment with interferon-beta, MCNU (Ranimustine), and radiotherapy for patients with previously untreated malignant glioma. J Neurooncol 2000;49:57-62.
9. Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M, et al. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 2005;65:7573-9.
10. Natsume A, Wakabayashi T, Ishii D, Maruta H, Fujii M, Shimato S, et al. A combination of IFN-beta and temozolomide in human glioma xenograft models: Implication of p53-mediated MGMT downregulation. Cancer Chemother Pharmacol 2007.
11. Aoki T, Takahashi JA, Ueba T, Oya N, Hiraoka M, Matsui K, et al. Phase II study of nimustine, carboplatin, vincristine, and interferon-beta with radiotherapy for glioblastoma multiforme: Experience of the Kyoto Neuro-Oncology Group. J Neurosurg 2006;105:385-91.
12. Hatano N, Wakabayashi T, Kajita Y, Mizuno M, Ohno T, Nakayashiki N, et al. Efficacy of post operative adjuvant therapy with human interferon beta, MCNU and radiation (IMR) for malignant glioma: Comparison among three protocols. Acta Neurochir 2000;142:633-8; discussion 9.
13. Watanabe T, Katayama Y, Yoshino A, Fukaya C, Yamamoto T. Human interferon beta, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocytomas. J Neurooncol 2005;72:57-62.
14. Yoshida J, Kajita Y, Wakabayashi T, Sugita K. Long-term follow-up results of 175 patients with malignant glioma: Importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir 1994;127:55-9.